Price Competition To Procrit Is Beginning To Stabilize, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.